<ul>
<li>罗素再平衡：3 只股票准备上涨</li>
</ul>
<p>Insmed, Inc.（纳斯达克：INSM - 免费报告）- HC Wainwright 在 12 月 18 日星期四向投资者发布的研究报告中下调了对 Insmed 2028 财年的每股收益预期。HC Wainwright 的分析师 A. Fein 现在预计这家生物制药公司将发布每股收益 3.15 美元，低于之前预测的 3.42 美元。HC Wainwright 对该股票给予 “买入” 评级，目标价为 230.00 美元。市场普遍预计 Insmed 当前全年的每股收益为（4.56 美元）。</p>
<p>其他股票分析师也对该股票发布了报告。Wolfe Research 在周四对 Insmed 的股票设定了 167.00 美元的目标价，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了对 Insmed 的 “卖出（d-）” 评级。富国银行在周四的研究报告中对 Insmed 设定了 195.00 美元的目标价。高盛集团在周一的研究报告中将 Insmed 的目标价从 225.00 美元上调至 258.00 美元，并给予该公司 “买入” 评级。最后，Cowen 在周四的研究报告中对 Insmed 设定了 241.00 美元的目标价。一位分析师给予该股票 “强烈买入” 评级，21 位给予 “买入” 评级，1 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 205.41 美元。</p>
<ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
<p><strong>查看我们关于 Insmed 的最新研究报告</strong></p>
<h2>Insmed 股票下跌 16.1%</h2>
<p>Insmed 股票在周五开盘价为 166.55 美元。该公司的速动比率为 4.34，流动比率为 4.63，债务股本比率为 0.59。该公司的市值为 355.2 亿美元，市盈率为-26.91，贝塔值为 1.01。该公司的 50 日移动平均价格为 187.41 美元，200 日移动平均价格为 142.30 美元。Insmed 的 52 周低点为 60.40 美元，52 周高点为 212.75 美元。</p>
<p>Insmed（纳斯达克：INSM - 获取免费报告）在 10 月 30 日星期四发布了季度财报。这家生物制药公司报告季度每股收益为（1.75 美元），低于市场普遍预期的（1.35 美元）0.40 美元。Insmed 的净利润率为-264.83%，股本回报率为-183.55%。该公司季度收入为 1.4234 亿美元，而分析师预期为 1.1433 亿美元。在去年同期，该公司每股收益为（1.27 美元）。该公司的季度收入同比增长 52.4%。</p>
<h2>Insmed 的内部交易</h2>
<p>在相关消息中，内部人士 Michael Alexander Smith 在 11 月 3 日星期一出售了 27,130 股公司的股票。该股票以 183.78 美元的平均价格出售，总价值为 4,985,951.40 美元。出售后，该内部人士持有 54,902 股公司股票，价值为 10,089,889.56 美元。这代表其持股比例减少了 33.07%。该交易在向证券交易委员会的备案中披露，相关信息可在此链接查看。此外，内部人士 Orlov S. Nicole Schaeffer 在 11 月 12 日星期三出售了 30,000 股该股票。该股票以 194.00 美元的平均价格出售，总交易额为 5,820,000.00 美元。交易完成后，该内部人士持有 36,461 股公司股票，价值约为 7,073,434 美元。该交易代表其持股比例减少了 45.14%。该交易的 SEC 备案提供了更多信息。在上个季度，内部人士出售了价值 28,480,051 美元的 147,130 股公司股票。3.00% 的股票由内部人士持有。</p>
<h2>Insmed 的机构交易</h2>
<p>大型投资者最近对该公司的持仓进行了调整。CIBC 私人财富集团在第三季度将其在 Insmed 的持仓提高了 42.1%。CIBC 私人财富集团现在拥有 179 股这家生物制药公司的股票，价值 26,000 美元，此前在该期间购买了 53 股。ORG Partners 在第二季度将其在 Insmed 的持仓提高了 220.2%。ORG Partners 现在拥有 285 股这家生物制药公司的股票，价值 28,000 美元，此前在上个季度购买了 196 股。Hilltop National Bank 在第二季度获得了 Insmed 的新持仓，价值约为 28,000 美元。Stone House Investment Management 在第三季度获得了 Insmed 的新持仓，价值约为 29,000 美元。最后，SBI 证券有限公司在第三季度将其在 Insmed 的持仓提高了 404.9%。SBI 证券有限公司现在拥有 207 股这家生物制药公司的股票，价值 30,000 美元，此前在上个季度购买了 166 股。</p>
<h2>关于 Insmed</h2>
<p>（获取免费报告）</p>
<p>Insmed Incorporated 是一家全球生物制药公司，致力于改善严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），该产品已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或没有替代治疗选择的抗菌药物组合的一部分。</p>
<h2>精选故事</h2>
<ul>
<li>我们更看好的五只股票比 Insmed 更好</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>博通股票暴跌 20%——但华尔街预计其将飙升至 500 美元</li>
<li>内部交易 - 你需要知道的事项</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>哪些华尔街分析师最准确？</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
<p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" original-src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ"/></p>
<p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
<h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
<p>在考虑 Insmed 之前，你需要听听这个。</p>
<p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
<p>虽然 Insmed 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
<p>在这里查看这五只股票</p>

INSM

<p>HC Wainwright 已将 Insmed, Inc. 的 2028 财年每股收益预估从 3.42 美元下调至 3.15 美元，维持 “买入” 评级，目标价为 230 美元。其他分析师的评级和目标价各不相同，平均评级为 “适度买入”，目标价为 205.41 美元。Insmed 的股票开盘价为 166.55 美元，近期注意到内部人士出售股票和机构交易活动</p>

<ul>
<li>Russell Rebalance: 3 Stocks Ready to Move Higher</li>
</ul>
<div class="lb-trans"><ul>
<li>罗素再平衡：3 只股票准备上涨</li>
</ul>
</div><p>Insmed, Inc. (NASDAQ:INSM - Free Report) - HC Wainwright cut their FY2028 earnings per share estimates for Insmed in a research note issued to investors on Thursday, December 18th. HC Wainwright analyst A. Fein now anticipates that the biopharmaceutical company will post earnings per share of $3.15 for the year, down from their prior forecast of $3.42. HC Wainwright has a &#34;Buy&#34; rating and a $230.00 price target on the stock. The consensus estimate for Insmed's current full-year earnings is ($4.56) per share.</p>
<div class="lb-trans"><p>Insmed, Inc.（纳斯达克：INSM - 免费报告）- HC Wainwright 在 12 月 18 日星期四向投资者发布的研究报告中下调了对 Insmed 2028 财年的每股收益预期。HC Wainwright 的分析师 A. Fein 现在预计这家生物制药公司将发布每股收益 3.15 美元，低于之前预测的 3.42 美元。HC Wainwright 对该股票给予 “买入” 评级，目标价为 230.00 美元。市场普遍预计 Insmed 当前全年的每股收益为（4.56 美元）。</p>
</div><p>Other equities analysts have also issued reports about the stock. Wolfe Research set a $167.00 price target on shares of Insmed and gave the stock an &#34;outperform&#34; rating in a report on Thursday. Weiss Ratings reissued a &#34;sell (d-)&#34; rating on shares of Insmed in a research report on Wednesday, October 8th. Wells Fargo &amp; Company set a $195.00 target price on Insmed in a research report on Thursday. The Goldman Sachs Group increased their price target on Insmed from $225.00 to $258.00 and gave the company a &#34;buy&#34; rating in a research note on Monday. Finally, Cowen set a $241.00 price target on Insmed in a research note on Thursday. One analyst has rated the stock with a Strong Buy rating, twenty-one have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the company. According to data from MarketBeat, the company has an average rating of &#34;Moderate Buy&#34; and an average price target of $205.41.</p>
<div class="lb-trans"><p>其他股票分析师也对该股票发布了报告。Wolfe Research 在周四对 Insmed 的股票设定了 167.00 美元的目标价，并给予该股票 “跑赢大盘” 的评级。Weiss Ratings 在 10 月 8 日星期三的研究报告中重新发布了对 Insmed 的 “卖出（d-）” 评级。富国银行在周四的研究报告中对 Insmed 设定了 195.00 美元的目标价。高盛集团在周一的研究报告中将 Insmed 的目标价从 225.00 美元上调至 258.00 美元，并给予该公司 “买入” 评级。最后，Cowen 在周四的研究报告中对 Insmed 设定了 241.00 美元的目标价。一位分析师给予该股票 “强烈买入” 评级，21 位给予 “买入” 评级，1 位给予 “持有” 评级，1 位给予 “卖出” 评级。根据 MarketBeat 的数据，该公司的平均评级为 “适度买入”，平均目标价为 205.41 美元。</p>
</div><ul>
<li>Stock Rotation is Underway: Here are the Winners Moving Forward</li>
</ul>
<div class="lb-trans"><ul>
<li>股票轮换正在进行：以下是未来的赢家</li>
</ul>
</div><p><strong>Check Out Our Latest Research Report on Insmed</strong></p>
<div class="lb-trans"><p><strong>查看我们关于 Insmed 的最新研究报告</strong></p>
</div><h2>Insmed Stock Down 16.1%</h2>
<div class="lb-trans"><h2>Insmed 股票下跌 16.1%</h2>
</div><p>Shares of Insmed stock opened at $166.55 on Friday. The company has a quick ratio of 4.34, a current ratio of 4.63 and a debt-to-equity ratio of 0.59. The company has a market cap of $35.52 billion, a P/E ratio of -26.91 and a beta of 1.01. The firm's 50 day moving average price is $187.41 and its 200-day moving average price is $142.30. Insmed has a 52-week low of $60.40 and a 52-week high of $212.75.</p>
<div class="lb-trans"><p>Insmed 股票在周五开盘价为 166.55 美元。该公司的速动比率为 4.34，流动比率为 4.63，债务股本比率为 0.59。该公司的市值为 355.2 亿美元，市盈率为-26.91，贝塔值为 1.01。该公司的 50 日移动平均价格为 187.41 美元，200 日移动平均价格为 142.30 美元。Insmed 的 52 周低点为 60.40 美元，52 周高点为 212.75 美元。</p>
</div><p>Insmed (NASDAQ:INSM - Get Free Report) last released its quarterly earnings results on Thursday, October 30th. The biopharmaceutical company reported ($1.75) EPS for the quarter, missing the consensus estimate of ($1.35) by ($0.40). Insmed had a negative net margin of 264.83% and a negative return on equity of 183.55%. The firm had revenue of $142.34 million for the quarter, compared to analysts' expectations of $114.33 million. During the same period in the previous year, the company posted ($1.27) earnings per share. The business's quarterly revenue was up 52.4% compared to the same quarter last year.</p>
<div class="lb-trans"><p>Insmed（纳斯达克：INSM - 获取免费报告）在 10 月 30 日星期四发布了季度财报。这家生物制药公司报告季度每股收益为（1.75 美元），低于市场普遍预期的（1.35 美元）0.40 美元。Insmed 的净利润率为-264.83%，股本回报率为-183.55%。该公司季度收入为 1.4234 亿美元，而分析师预期为 1.1433 亿美元。在去年同期，该公司每股收益为（1.27 美元）。该公司的季度收入同比增长 52.4%。</p>
</div><h2>Insider Transactions at Insmed</h2>
<div class="lb-trans"><h2>Insmed 的内部交易</h2>
</div><p>In related news, insider Michael Alexander Smith sold 27,130 shares of the company's stock in a transaction that occurred on Monday, November 3rd. The stock was sold at an average price of $183.78, for a total value of $4,985,951.40. Following the sale, the insider owned 54,902 shares in the company, valued at $10,089,889.56. This represents a 33.07% decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities &amp; Exchange Commission, which is available at this hyperlink. Also, insider Orlov S. Nicole Schaeffer sold 30,000 shares of the stock in a transaction that occurred on Wednesday, November 12th. The stock was sold at an average price of $194.00, for a total transaction of $5,820,000.00. Following the completion of the transaction, the insider owned 36,461 shares in the company, valued at approximately $7,073,434. This trade represents a 45.14% decrease in their position. The SEC filing for this sale provides additional information. In the last quarter, insiders sold 147,130 shares of company stock worth $28,480,051. 3.00% of the stock is owned by insiders.</p>
<div class="lb-trans"><p>在相关消息中，内部人士 Michael Alexander Smith 在 11 月 3 日星期一出售了 27,130 股公司的股票。该股票以 183.78 美元的平均价格出售，总价值为 4,985,951.40 美元。出售后，该内部人士持有 54,902 股公司股票，价值为 10,089,889.56 美元。这代表其持股比例减少了 33.07%。该交易在向证券交易委员会的备案中披露，相关信息可在此链接查看。此外，内部人士 Orlov S. Nicole Schaeffer 在 11 月 12 日星期三出售了 30,000 股该股票。该股票以 194.00 美元的平均价格出售，总交易额为 5,820,000.00 美元。交易完成后，该内部人士持有 36,461 股公司股票，价值约为 7,073,434 美元。该交易代表其持股比例减少了 45.14%。该交易的 SEC 备案提供了更多信息。在上个季度，内部人士出售了价值 28,480,051 美元的 147,130 股公司股票。3.00% 的股票由内部人士持有。</p>
</div><h2>Institutional Trading of Insmed</h2>
<div class="lb-trans"><h2>Insmed 的机构交易</h2>
</div><p>Large investors have recently made changes to their positions in the business. CIBC Private Wealth Group LLC lifted its position in Insmed by 42.1% during the third quarter. CIBC Private Wealth Group LLC now owns 179 shares of the biopharmaceutical company's stock valued at $26,000 after purchasing an additional 53 shares during the period. ORG Partners LLC raised its stake in shares of Insmed by 220.2% during the 2nd quarter. ORG Partners LLC now owns 285 shares of the biopharmaceutical company's stock valued at $28,000 after buying an additional 196 shares during the last quarter. Hilltop National Bank acquired a new position in shares of Insmed in the 2nd quarter valued at about $28,000. Stone House Investment Management LLC acquired a new position in shares of Insmed in the 3rd quarter valued at about $29,000. Finally, SBI Securities Co. Ltd. boosted its stake in shares of Insmed by 404.9% in the third quarter. SBI Securities Co. Ltd. now owns 207 shares of the biopharmaceutical company's stock worth $30,000 after buying an additional 166 shares during the last quarter.</p>
<div class="lb-trans"><p>大型投资者最近对该公司的持仓进行了调整。CIBC 私人财富集团在第三季度将其在 Insmed 的持仓提高了 42.1%。CIBC 私人财富集团现在拥有 179 股这家生物制药公司的股票，价值 26,000 美元，此前在该期间购买了 53 股。ORG Partners 在第二季度将其在 Insmed 的持仓提高了 220.2%。ORG Partners 现在拥有 285 股这家生物制药公司的股票，价值 28,000 美元，此前在上个季度购买了 196 股。Hilltop National Bank 在第二季度获得了 Insmed 的新持仓，价值约为 28,000 美元。Stone House Investment Management 在第三季度获得了 Insmed 的新持仓，价值约为 29,000 美元。最后，SBI 证券有限公司在第三季度将其在 Insmed 的持仓提高了 404.9%。SBI 证券有限公司现在拥有 207 股这家生物制药公司的股票，价值 30,000 美元，此前在上个季度购买了 166 股。</p>
</div><h2>About Insmed</h2>
<div class="lb-trans"><h2>关于 Insmed</h2>
</div><p>(Get Free Report)</p>
<div class="lb-trans"><p>（获取免费报告）</p>
</div><p>Insmed Incorporated is a global biopharmaceutical company on a mission to transform the lives of patients with serious and rare diseases. Insmed's first commercial product is ARIKAYCE® (amikacin liposome inhalation suspension), which is approved in the United States for the treatment of Mycobacterium avium complex (MAC) lung disease as part of a combination antibacterial drug regimen for adult patients with limited or no alternative treatment options.</p>
<div class="lb-trans"><p>Insmed Incorporated 是一家全球生物制药公司，致力于改善严重和罕见疾病患者的生活。Insmed 的首个商业产品是 ARIKAYCE®（阿米卡星脂质体吸入悬液），该产品已在美国获得批准，用于治疗结核分枝杆菌复合体（MAC）肺病，作为成人患者有限或没有替代治疗选择的抗菌药物组合的一部分。</p>
</div><h2>Featured Stories</h2>
<div class="lb-trans"><h2>精选故事</h2>
</div><ul>
<li>Five stocks we like better than Insmed</li>
<li>Diversification Can Smooth Returns And Mitigate Portfolio Risk</li>
<li>Broadcom Stock Crashes 20%—But Wall Street Sees It Soaring to $500</li>
<li>Insider Trading - What You Need to Know</li>
<li>Forget the Chips: 4 Industrial Plays for the AI Rebound</li>
<li>Which Wall Street Analysts are the Most Accurate?</li>
<li>MongoDB Could Hit Record Highs—But You’ll Need to Move Fast</li>
</ul>
<div class="lb-trans"><ul>
<li>我们更看好的五只股票比 Insmed 更好</li>
<li>多元化可以平滑收益并降低投资组合风险</li>
<li>博通股票暴跌 20%——但华尔街预计其将飙升至 500 美元</li>
<li>内部交易 - 你需要知道的事项</li>
<li>忘掉芯片：AI 反弹的 4 个工业投资机会</li>
<li>哪些华尔街分析师最准确？</li>
<li>MongoDB 可能创下新高——但你需要迅速行动</li>
</ul>
</div><p><img src="https://imageproxy.pbkrs.com/https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx/query-UHJlZml4PU5BU0RBUSZTeW1ib2w9SU5TTQ" alt="" original-src="https://www.marketbeat.com/scripts/EarningsEstimatesChart.ashx?Prefix=NASDAQ&amp;Symbol=INSM"/></p>
<p><em>This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.</em></p>
<div class="lb-trans"><p><em>此即时新闻提醒由叙事科学技术和 MarketBeat 的金融数据生成，旨在为读者提供最快的报道和公正的覆盖。请将有关此故事的任何问题或评论发送至 contact@marketbeat.com.</em></p>
</div><h2>Should You Invest $1,000 in Insmed Right Now?</h2>
<div class="lb-trans"><h2>你现在应该投资 1,000 美元在 Insmed 吗？</h2>
</div><p>Before you consider Insmed, you'll want to hear this.</p>
<div class="lb-trans"><p>在考虑 Insmed 之前，你需要听听这个。</p>
</div><p>MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Insmed wasn't on the list.</p>
<div class="lb-trans"><p>MarketBeat 每天跟踪华尔街顶级评级和表现最佳的研究分析师及其推荐给客户的股票。MarketBeat 已识别出五只股票，顶级分析师正在悄悄地向客户推荐在更广泛的市场注意到之前购买……而 Insmed 并不在名单上。</p>
</div><p>While Insmed currently has a Moderate Buy rating among analysts, top-rated analysts believe these five stocks are better buys.</p>
<div class="lb-trans"><p>虽然 Insmed 目前在分析师中获得了中等买入评级，但顶级分析师认为这五只股票更值得购买。</p>
</div><p>View The Five Stocks Here</p>
<div class="lb-trans"><p>在这里查看这五只股票</p>
</div>

HC Wainwright 发布了对 Insmed 的 2028 财年盈利预测